Chemomab Therapeutics ADR Aktie

Chemomab and Scipher Medicine are completing an all-stock transaction; the combined company will operate as Scipher Medicine and trade on NASDAQ under the ticker SCIP. Chemomab shareholders will receive about 32% and Scipher shareholders 68% of the diluted shares; the combined valuation is $150 million before a $30 million private placement. A consortium led by Northpond Ventures secures the $30 million financing, and liquidity is expected to extend into the second half of 2028. The goal is to advance Nebokitug (anti-CCL24) into a phase 2 trial for rheumatoid arthritis with top-line results expected in H1 2028; Dr. Reginald Seeto will be CEO, and Chemomab CEO Adi Mor will join the board. The transaction was unanimously approved by both boards and is expected to close in Q4 2026 after customary approvals. » Altro su de.investing.com

Chemomab Therapeutics released on Nov. 20, 2025 the results for the quarter ended Sept. 30, 2025. Loss per share was $0.32, compared with a loss of $0.80 in the year-ago quarter. No further financial figures were reported. » Altro su finanzen.net